Baker Chad R Sells 8,990 Shares of Vertex Pharmaceuticals

Insider selling activity at the pharmaceutical company

Mar. 27, 2026 at 7:35am

Got story updates? Submit your updates here. ›

Baker Chad R, an executive at Vertex Pharmaceuticals Incorporated, reduced his position in the company by selling 8,990 shares during the fourth quarter. This sale represented a 92.3% decrease in his holdings, leaving him with only 750 shares valued at $340,000 as of the most recent SEC filing.

Why it matters

Insider trading activity can provide insights into management's views on a company's prospects. While a single sale does not necessarily indicate broader concerns, it may signal a shift in sentiment or a desire to diversify holdings. Investors often monitor insider transactions as one data point in evaluating a stock.

The details

According to the SEC filing, Baker Chad R sold 8,990 shares of Vertex Pharmaceuticals at an average price of $440 per share, resulting in total proceeds of approximately $3.96 million. This reduced his overall stake in the company to just 750 shares, down from the 9,740 shares he previously held.

  • The share sale occurred during the fourth quarter of the year.

The players

Baker Chad R

An executive at Vertex Pharmaceuticals Incorporated who previously held a larger position in the company's stock.

Vertex Pharmaceuticals Incorporated

A Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases, particularly cystic fibrosis.

Got photos? Submit your photos here. ›

The takeaway

This insider sale, while not necessarily indicative of broader concerns, does highlight a shift in one executive's position within Vertex Pharmaceuticals. Investors may want to monitor any further changes in insider ownership or other developments that could impact the company's outlook.